Semaglutide vs Tirzepatide vs Retatrutide: What the Evidence Says

Medically reviewed by Dr. Hootan Zandifar, MD, Medical Director, Regen Therapy MD (UCLA David Geffen School of Medicine). Educational information only — not medical advice; individual results vary.

Important disclaimers (please read first)

1. This is education only. It is not medical advice, not a diagnosis, and not a treatment plan for you.
2. We are not saying you are a candidate. Nothing here confirms that you are (or are not) a fit for any medicine or program. At Regen Therapy MD, a physician decides only after a proper consult.
3. Results vary. Published trial averages describe people in studies under study rules. They are not guarantees of any result for any reader.
4. Brand FDA-approved products are not the same as compounded versions. An FDA-approved brand medicine (for example, a branded semaglutide or tirzepatide product) and a compounded formulation are not equivalent or interchangeable. Do not assume they match in quality, strength, purity, labeling, or evidence.
5. Retatrutide is investigational. That means it is still being studied and is not an FDA-approved therapy for any use. The FDA has also said retatrutide cannot be used in compounding under federal law, and it has not been found safe and effective as an approved product. This page does not mean retatrutide is available as an approved medicine.
6. These medicines have real risks. Talk with a clinician. Some approved GLP-1 products carry a boxed warning about thyroid C-cell tumors seen in rodents, and they may not be right if you or your family have certain thyroid cancers (such as medullary thyroid carcinoma) or MEN2. Stomach and gut side effects are common in trials. This page does not give dosing, step-up schedules, or protocols—ask a licensed clinician.
7. Licensure and shipping. Any telehealth or shipping, if offered, applies only where we are licensed. This page does not claim service in all 50 states.
8. How Regen frames next steps. A free discovery call is a non-clinical chat to help you learn what you may be a candidate for—never that you are one.
9. Claims and testimonials. No made-up testimonials appear here. We lean on cited sources (PubMed PMIDs and FDA pages). Third-party research sites are secondary context only and are not prescribing authority.

Quick glossary

• GLP-1 — a gut hormone pathway that helps regulate appetite and blood sugar; many weight and diabetes medicines act on it.
• GIP — another gut hormone pathway; some newer medicines act on GIP and GLP-1 together.
• Investigational — still in clinical trials; not FDA-approved for everyday prescribing.
• Compounded — a custom-prepared version from a compounding pharmacy; not the same as an FDA-approved brand product.

A simple way to compare them

People often search semaglutide vs tirzepatide vs retatrutide because the names sound similar. In practice, you are comparing three different things: how each medicine works, whether it is FDA-approved, and what studies actually measured.

This page shares educational context. A Regen physician visit is where your history, labs, safety checks, and any product choice (if any) are decided.

Semaglutide

Semaglutide works on the GLP-1 pathway. FDA-approved semaglutide products are prescription medicines. Each brand has its own label, uses, and warnings. Different brand products are not automatically interchangeable with each other—or with compounded versions.

What to keep in mind: use is clinician-directed; diet and activity are part of labeled chronic weight-management frameworks for approved products; safety labeling includes serious risks that need a personalized review.

What this page will not do: list doses, titration schedules, stacking protocols, or suggest you start therapy from an article.

Tirzepatide

Tirzepatide works on both GIP and GLP-1 pathways. FDA-approved tirzepatide products also have product-specific uses and safety labeling. Research comparing tirzepatide with semaglutide exists in peer-reviewed journals. Those results describe people in trials, not a promise for clinic visitors.

One often-cited head-to-head study in adults with obesity without diabetes is SURMOUNT-5 (Aronne et al.). In that trial design, tirzepatide showed greater average percent weight reduction than semaglutide at 72 weeks (PubMed PMID 40353578). Trial superiority in a study group is not a guarantee for any individual. Side-effect patterns (often gut-related) still need clinical judgment.

Retatrutide (investigational)

Retatrutide is an investigational medicine that acts on three pathways: GIP, GLP-1, and glucagon. Phase 2 obesity research (Jastreboff et al., NEJM) reported large average weight reductions over 48 weeks versus placebo in trial arms (PubMed PMID 37366315). Phase 3 programs have been discussed in the literature, but being studied is not the same as being approved.

Compliance points for this molecule:

• Do not read this page as saying retatrutide is FDA-approved or routinely available as an approved therapy.
• FDA consumer guidance on unapproved GLP-1-related products states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition as an approved drug component (FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss).
• Online “research chemical” sellers are not a substitute for regulated care.

Brand FDA-approved medicines vs compounded products

The FDA has warned that unapproved versions of GLP-1 drugs used for weight loss can be risky. They do not go through the same premarket review for safety, effectiveness, and quality as approved drugs. Compounded drugs are not FDA-approved. Even when compounding is legally allowed in specific situations, compounded products are not the same as brand FDA-approved medicines.

Practical takeaway: ask your clinician which product category is being discussed, why, and how monitoring will work. Do not treat a social-media protocol like a labeled medicine.

How to read “vs” charts without turning them into guarantees

Online comparison tables often mix different trials, doses, populations, and timepoints. Even careful research summaries are models of published studies, not personal forecasts.

Safer reading habits:

1. Check whether a comparison is head-to-head (same trial) or indirect (different studies pieced together).
2. Note whether the study enrolled people with or without diabetes—responses can differ.
3. Separate how much weight changed from how people felt and who stopped the medicine.
4. Remember investigational agents do not have a completed approval package.

Secondary web resources such as Peptide Schedule may organize public discussion, but they are not FDA labels. They often include dosing or protocol tools that this page intentionally omits.

Safety — high level only (no dosing)

For FDA-approved incretin medicines, clinicians review the full prescribing information, including boxed warnings and contraindications where they apply (for example, thyroid C-cell tumor boxed-warning language on certain semaglutide labels; gut side effects; other warnings that can change when labels update). Retatrutide’s published phase 2 experience also reported dose-related gut events and heart-rate changes in trial settings (PMID 37366315)—still not an approval.

What to bring to a visit: your medication list, any history of pancreatitis or gallbladder disease, thyroid cancer / MEN2 risk factors, pregnancy plans, and prior use of similar medicines. Do not self-dose from blogs or calculators.

FAQ

Are semaglutide and tirzepatide the same?

No. Both act on gut-hormone pathways, but tirzepatide is a dual GIP/GLP-1 medicine while semaglutide is a GLP-1 medicine. FDA-approved products also differ by brand label and approved use. A clinician matches any option to your history—not a blog chart.

Is retatrutide available as an FDA-approved medicine?

No. Retatrutide remains investigational and is not FDA-approved. The FDA has also stated it cannot be used in compounding under federal law. Treat online “availability” claims with extreme caution.

Do trial weight-loss percentages mean I will get the same result?

No. Trial averages describe study populations under study rules. Individual results vary. Nothing in this article guarantees an outcome.

How do I start a conversation at Regen Therapy MD?

Book online via PatientNow or Contact Us, or call (424) 349-6008. A free discovery call is non-clinical and explores what you may be a candidate for.

Talk with Regen Therapy MD

If you want a physician-directed conversation about metabolic or weight-management options that may or may not include these medicines, start with booking—not with a self-selected protocol:

• Book: https://book.mypatientnow.com/practice/TqZLiT
• Contact: https://www.regentherapymd.com/contact-us
• Phone: (424) 349-6008
• Email: book@regentherapymd.com

Clinic: Beverly Hills — 8920 Wilshire Blvd, Suite 604

Disclaimers

Educational content only — not medical advice, diagnosis, or a treatment plan. Does not confirm candidacy. Individual results vary; no outcome guarantees. FDA-approved brand products and compounded formulations are not equivalent or interchangeable. Retatrutide is investigational / not FDA-approved and is not presented here as an available approved therapy; FDA notes compounding restrictions. Side-effect and boxed-warning discussions are high-level; review full labels with a clinician—no dosing or protocols on this page. Telehealth/shipping only where licensed; no “all 50 states” claim. Free discovery call = non-clinical. No fabricated testimonials; sources cited below.

Sources

1. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PubMed PMID 40353578.
2. Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. PubMed PMID 37366315.
3. U.S. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (includes compounding / retatrutide statements).
4. Secondary orientation only: peptideschedule.com peptide/compare pages (not used for dosing on this page).